SG Americas Securities LLC increased its holdings in Embecta Corp. (NASDAQ:EMBC – Get Rating) by 14.2% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 8,631 shares of the company’s stock after buying an additional 1,072 shares during the period. SG Americas Securities LLC’s holdings in Embecta were worth $218,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently made changes to their positions in the company. BlackRock Inc. bought a new position in shares of Embecta during the third quarter valued at about $258,676,000. Vanguard Group Inc. bought a new position in shares of Embecta during the third quarter valued at about $197,911,000. Yacktman Asset Management LP grew its stake in shares of Embecta by 10.9% during the fourth quarter. Yacktman Asset Management LP now owns 2,566,207 shares of the company’s stock valued at $64,899,000 after buying an additional 252,977 shares during the last quarter. State Street Corp bought a new stake in shares of Embecta in the third quarter worth about $68,114,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Embecta in the third quarter worth about $29,545,000. Hedge funds and other institutional investors own 93.45% of the company’s stock.
Embecta Price Performance
NASDAQ EMBC opened at $29.58 on Thursday. Embecta Corp. has a 1 year low of $22.30 and a 1 year high of $36.64. The business’s 50-day moving average is $29.15 and its 200 day moving average is $29.31.
Embecta Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Monday, March 13th. Shareholders of record on Monday, February 27th were issued a dividend of $0.15 per share. The ex-dividend date was Friday, February 24th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 2.03%.
Insider Buying and Selling
In related news, Director David F. Melcher purchased 3,100 shares of the business’s stock in a transaction that occurred on Wednesday, February 15th. The shares were bought at an average price of $32.51 per share, for a total transaction of $100,781.00. Following the purchase, the director now directly owns 21,465 shares of the company’s stock, valued at approximately $697,827.15. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.22% of the stock is currently owned by company insiders.
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally.
- Get a free copy of the StockNews.com research report on Embecta (EMBC)
- Occidental Petroleum: Will Buffet Buy More?
- 5 Best Healthcare Sector ETFs
- Electronic Arts Has Game But Can Share Price Move Higher?
- Wendy’s May Have Just Become A Value Play
- Rivian Leads EV Startups But Will The Stock Move Higher?
Want to see what other hedge funds are holding EMBC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Embecta Corp. (NASDAQ:EMBC – Get Rating).
Receive News & Ratings for Embecta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Embecta and related companies with MarketBeat.com's FREE daily email newsletter.